Details of the Drug Reposition

General Information of This Drug (ID: DMTE8DC)

Drug Name
Pozelimab   DMTE8DC
Synonyms REGN3918
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Large B Cell Lymphoma DISN4RT4 N.A. Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal nocturnal haemoglobinuria DISBHMYH 3A21.0 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761339
2 ClinicalTrials.gov (NCT04888507) Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy. U.S. National Institutes of Health.